StockData

Caris Life Sciences vs Fortrea

CAI and FTRE side by side, both in health services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How CAI and FTRE compare

Caris Life Sciences is the larger company, worth 3.0 times as much as Fortrea ($5.6B against $1.9B).

Caris Life Sciences grew revenue faster over the last twelve months (61.5% versus −3.4% for Fortrea).

Caris Life Sciences keeps more of each dollar of sales as profit, with a net margin of 9.2% compared with −2.6% at Fortrea.

Caris Life Sciences scores higher on the StockData Score (7 against 4 for Fortrea), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricCAIFTRE
Size and price
Market cap$5.6B$1.9B
Share price$19.94$19.59
Change, 1 year−16.4%88.2%
Beta (5Y)2.531.30
Employees1,84614K
StockData Score
Total score7 (better)4
Valuation score00
Growth score12 (better)
Performance score3 (better)2
Health score3 (better)0
Dividend score00
Valuation
P/S5.4×0.7× (better)
P/B8.8×3.6× (better)
EV/EBITDA36.5×29.8× (better)
P/FCF195×11.2× (better)
FCF yield0.51%8.9% (better)
Fair value$10.35$12.57
Margin of safety−92.6%−55.9% (better)
Growth
Revenue growth (TTM)61.5% (better)−3.4%
Profitability
Gross margin–20.0%
Operating margin13.4% (better)0.48%
Net margin9.2% (better)−2.6%
FCF margin2.8%6.3% (better)
Return on equity17.2% (better)−12.3%
Return on invested capital26.8% (better)0.69%
Financial health
Debt / equity0.61 (better)1.98
Net debt / EBITDA1.79 (better)9.12
Interest coverage3.3×–
Current ratio6.71 (better)0.97
Altman Z-score4.73 (better)0.76
Piotroski F-score6 (better)3
Dividends and buybacks
Buyback yield0.56%–
Shareholder yield0.56% (better)0.00%
Ownership
Held by institutions54.5%104%
Held by insiders64.1%3.9%
Insider net buying, 12 months−$27.4M−$4.7M (better)
Superinvestors holding2–
Short interest, % of float11.3%9.2%

Go deeper

Other comparisons

For information only, not investment advice. Check the source filings before relying on any figure.